Influence of time-dose-relationships in therapeutic nuclear medicine applications on biological effectiveness of irradiation Consequences for dosimetry;Einfluss der Dosisleistung Nukleormedizinischer Therapie auf die Biologische Strahlenwirkung Konsequenzen für die Dosimetrie

NuklearMedizin

Volumn 47, Issue 5, 2008, Pages 205-209

  Oehme, L ^a   Dorr W ^a   Wust, P ^b   Kotzerke, J ^a  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Biological effective dose; Dosimetry, 188; Isoeffectiveness; Nephrotoxicity; Re

Indexed keywords

IODINE 131; LUTETIUM 177; RHENIUM 188; YTTRIUM 90; DIAGNOSTIC AGENT; RADIOISOTOPE;

ARTICLE; DOSIMETRY; EXTERNAL BEAM RADIOTHERAPY; HALF LIFE TIME; IRRADIATION; RADIATION DOSE FRACTIONATION; TISSUE SPECIFICITY; CHEMISTRY; HUMAN; KIDNEY; METHODOLOGY; NUCLEAR MEDICINE; PATHOLOGY; RADIATION DOSE; RADIATION EXPOSURE; RADIATION RESPONSE;

DOSE FRACTIONATION; DOSE-RESPONSE RELATIONSHIP, RADIATION; HALF-LIFE; HUMANS; KIDNEY; NUCLEAR MEDICINE; RADIATION TOLERANCE; RADIOISOTOPES; RADIOTHERAPY DOSAGE;

EID: 58149352857     PISSN: 00295566     EISSN: None     Source Type: Journal    
DOI: 10.3413/nukmed-0151     Document Type: Article

References (38)

1. Barendsen GW. Dose fractionation, dose rate and iso-effect relationships for normal tissue responses. Int J Radiat Oncol Biol Phys 1982; 8: 1981-1997.
2. 90Y-DOTATOC: relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 2005; 46 Suppl 1:99S-106S.
3. Bodey RK, Flux GD, Evans PM. Combining dosimetry for targeted radionuclide and external beam therapies using the biologically effective dose. Cancer Biother Radiopharm 2003; 18: 89-97.
4. Bouchet LG, Bolch WE, Blanco HP et al. MIRD Pamphlet No 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 2003; 44: 1113-1147.
5. Cavenagh EC, Weinberger E, Shaw DW et al. Hematopoietic marrow regeneration in pediatric patients undergoing spinal irradiation: MR depiction. AJNR Am J Neuroradiol 1995; 16:461-467.
6. 90Y-labeled ibritumomab tiuxetan therapy: possibility of increasing administered activity on the base of biological effective dose evaluation. Preliminary results. Cancer Biother Radiopharm 2007;22:113-120.
7. Cohen EP, Moulder JE, Robbins ME. Radiation nephropathy caused by yttrium 90. Lancet 2001;358:1102-1103.
8. 90Y-DOTATOC. Eur J Nucl Med 2001; 28:1552-1554.
9. Dale RG. The application of the linear-quadratic dose-effect equation to fractionated and protracted radiotherapy. Br J Radiol 1985;58:515-528.
10. Dale RG. Dose-rate effects in targeted radiotherapy. Phys Med Biol 1996;41:1871-1884.
11. Emami B, Lyman J, Brown A et al. Tolerance of normal tissue to therapeutic irradiation. Int J Radiât Oncol Biol Phys 1991; 21:109-122.
12. Glatting G, Landmann M, Wunderlich A et al. Internal radionuclide therapy: software for treatment planning using tomographic data. Nuklearmedizin 2006;45:269-272.
13. Herrmann T, Baumann M, Dörr W Klinische Strahlenbiologie - kurz und bündig. München: Elsevier 2006.
14. Joiner MC, Bentzen SM. Time-dose relationships: the linear-quadratic approach. In: Steel GG (ed). Basic clinical radiobiology Third ed. London: Edward Arnold Ltd. 2001:120-133.
15. Joiner MC, Johns H. Renal damage in the mouse: the response to very small doses per fraction. Radiât Res 1988; 114: 385-398.
16. Kal HB, van Kempen-Harteveld ML. Renal dysfunction after total body irradiation: dose-effect relationship. Int J Radiat Oncol Biol Phys 2006;65:1228-1232.
17. Kauczor HU, Dieti B, Brix G et al. Fatty replacement of bone marrow after radiation therapy for Hodgkin disease: quantification with chemical shift imaging. J Magn Reson Imaging 1993;3:575-580.
18. Kauczor HU, Dietl B, Kreitner KF et al. Bone marrow changes following radiotherapy. Results of MR tomography. Radiologe 1992;32:516-522.
19. Kost S, Dorr W, Keinert K et al. Effect of dose and dose-distribution in damage to the kidney following abdominal radiotherapy. Int J Radiat Biol 2002; 78: 695-702.
20. Lambert B, Cybulla M, Weiner SM et al. Renal toxicity after radionuclide therapy. Radiât Res 2004;161:607-611.
21. Luxton RW Radiation nephritis. A long-term study of 54 patients. Lancet 1961;2:1221-1224.
22. 131I-labeled anti-CD45 antibody, combined with cyclophosphamide and total body irradiation. Blood 1995; 85:1122-1131.
23. Millar WT Application of the linear-quadratic model with incomplete repair to radionuclide directed therapy. Br J Radiol 1991;64:242-251.
24. O'Donoghue J. Relevance of external beam doseresponse relationships to kidney toxicity associated with radionuclide therapy. Cancer Biother Radiopharm2004; 19: 378-387.
25. Prideaux AR, Song H, Hobbs RF et al. Three-dimensional radiobiologic dosimetry: application of radiobiologic modeling to patient-specific 3-dimensional imaging-based internal dosimetry. J Nucl Med 2007; 48:1008-1016.
26. Reske SN, Bunjes D, Buchmann I et al. Targeted bone marrow irradiation in the conditioning of high-risk leukaemia prior to stem cell transplantation. Eur J Nucl Med 2001; 28: 807-815.
27. Röttinger EM, Bartkowiak D, Bunjes D et al. Enhanced renal toxicity of total body irradiation combined with radioimmunotherapy Strahlenther Onkol 2003; 179: 702-707.
28. Stabin MG. MIRDOSE: personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 1996; 37: 538-546.
29. Stabin MG, Sparks RB, Crowe E. OLINDA/EXM: the second-generation personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 2005; 46:1023-1027.
30. 90Y)DOTATOC therapy: results and evaluation of a combined gamma camera/probe approach. Eur J Nucl Med Mol Imaging 2006; 33 : 1328-1336.
31. Steel GGe. Basic clinical radiobiology London: Arnold 2002.
32. Stewart FA, Oussoren Y, Luts A et al. Repair of sublethal radiation injury after multiple small doses in mouse kidney: an estimate of flexure dose. Int J Radiat Oncol Biol Phys 1987; 13: 765-772.
33. Thames HD An 'incomplete-repair' model for survival after fractionated and continuous irradiations. Int J Radiat Biol Relat Stud Phys Chem Med 1985;47:319-339.
34. Thames HD, Bentzen SM, Turesson I et al. Fractionation parameters for human tissues and tumors. Int J Radiat Biol 1989; 56: 701-710.
35. Thames HD, Bentzen SM, Turesson I et al. Time-dose factors in radiotherapy: a review of the human data. Radiother Oncol 1990; 19:219-235.
36. Thames HD Jr, Rozell ME, Tucker SL et al. Direct analysis of quantal radiation response data. Int J Radiât Biol Relat Stud Phys Chem Med 1986; 49: 999-1009.
37. Tucker SL, Thames HD Jr. Flexure dose: the low-dose limit of effective fractionation. Int J Radiat Oncol Biol Phys 1983; 9:1373-1383.
38. Van Rongen E, Kuijpers WC, Madhuizen HT Fractionation effects and repair kinetics in rat kidney. Int J Radiat Oncol Biol Phys 1990; 18: 1093-1106.